BTBD1 inhibitors are a class of chemical compounds designed to interfere with the function of the BTBD1 protein, which is a member of the BTB (BRIC-a-brac, Tramtrack, Broad complex) domain-containing family of proteins. BTBD1 is known to play a role in various cellular processes, including ubiquitination and proteasomal degradation. The inhibitors targeting this protein work by binding to its active sites or interacting with its structure in a way that impedes its normal function. This interaction can lead to the stabilization of proteins that are normally marked for degradation by the ubiquitin-proteasome system, indirectly affecting cellular pathways that rely on protein turnover for regulation. The design of BTBD1 inhibitors is based on the understanding of the protein's structure and the specific domains that are essential for its activity. By inhibiting BTBD1, these compounds can alter the protein's ability to participate in the post-translational modification of other proteins, thus affecting the cellular homeostasis and signaling pathways in which BTBD1 is involved.
The specificity of BTBD1 inhibitors is crucial, as it ensures that the compounds selectively target the BTBD1 protein without affecting other proteins with similar domains or functions. This specificity is achieved through precise molecular interactions, often involving the formation of hydrogen bonds, hydrophobic interactions, and van der Waals forces between the inhibitor and specific amino acid residues within the BTBD1 protein. The compounds often possess a high binding affinity for BTBD1, ensuring that they can effectively compete with natural substrates or other interacting molecules. The development of BTBD1 inhibitors is a sophisticated process that involves iterative cycles of design, synthesis, and testing to optimize the efficacy and selectivity of these compounds. As a result, BTBD1 inhibitors represent a targeted approach to modulating the activity of this protein, which is expected to have significant effects on the cellular processes it governs.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. Inhibition of kinases can prevent phosphorylation of BTBD1, thereby reducing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase inhibitor (PI3K inhibitor). PI3K signaling is involved in many cellular processes, including potentially the regulation of BTBD1. Inhibiting PI3K could reduce BTBD1 activity by limiting its post-translational modifications. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can regulate protein synthesis and degradation. Through inhibiting mTOR, the stability and activity of BTBD1 could be indirectly reduced. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor, specifically inhibiting CDK1/CDK2. CDKs might be involved in the regulation of BTBD1, thus its inhibition could result in decreased BTBD1 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. The p38 MAPK pathway may influence BTBD1 function, and inhibiting this pathway could lead to decreased activation of BTBD1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which blocks the MAPK/ERK pathway. This could lead to reduced activity of BTBD1 if BTBD1 is regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. JNK pathway inhibition could reduce the functional activity of BTBD1 through indirect regulatory mechanisms. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. By inhibiting proteasome activity, it could lead to the accumulation of ubiquitinated proteins, potentially affecting BTBD1 stability and function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is another proteasome inhibitor, which could indirectly decrease the functional activity of BTBD1 through stabilization of proteins that may regulate BTBD1 activity. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide, a modulator of the ubiquitin-proteasome system, could affect BTBD1 by modulating proteins that are involved in the ubiquitination and subsequent degradation of BTBD1. | ||||||